CJC-1295 no DAC / Ipamorelin Blend
CJC/Ipa Blend · CJC + Ipamorelin
CJC-1295 no DAC / Ipamorelin Blend is the most widely prescribed pre-mixed growth hormone secretagogue combination available from compounding pharmacies. It pairs Modified GRF(1-29) (the GHRH signal) with Ipamorelin (the cleanest GHRP), producing amplified pulsatile GH release through dual-receptor stimulation while maintaining the best side effect profile of any GH blend. This is the default starting point for GH optimization in peptide protocols.
Starting dose. 100mcg CJC + 100mcg Ipamorelin per injection
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
This blend works through simultaneous activation of two independent pathways on pituitary somatotroph cells:
CJC-1295 no DAC (Mod GRF 1-29)
Binds GHRH receptors on pituitary somatotrophs, activating the cAMP/PKA signaling cascade to prime and release stored GH granules. The four amino acid substitutions (Ala2, Glu8, Ala15, Leu27) protect against DPP-IV degradation, extending the half-life to approximately 30 minutes versus 7-10 minutes for native GHRH. Without the DAC (Drug Affinity Complex) linker, it produces acute GH pulses rather than sustained elevation, preserving natural pulsatile GH patterns.
Ipamorelin
Binds GHS-R1a (ghrelin receptor) on pituitary somatotrophs, triggering GH release through the PLC/IP3/PKC pathway - entirely separate from the GHRH pathway. Also suppresses somatostatin release, removing the natural brake on GH secretion. Unlike GHRP-6 and GHRP-2, Ipamorelin does not significantly activate cortisol, prolactin, or appetite pathways, providing the cleanest GH signal of any GHRP.
Synergistic Amplification
The simultaneous GHRH signal (CJC) and GHRP signal (Ipamorelin) converge on somatotrophs through independent intracellular pathways, producing GH pulses 3-5x greater than either peptide alone. This mimics the body's natural dual-signal GH regulation system, where GHRH and ghrelin coordinate pulsatile release.
What to expect
Days 1-7: Improved sleep quality is typically the first noticeable effect, often within the first few nights. Deeper sleep, more vivid dreams. Possible mild water retention as GH levels rise. Transient flushing or tingling post-injection is common and harmless. No significant appetite change (Ipamorelin is appetite-neutral).
Weeks 2-6: Body composition changes becoming visible - reduced abdominal fat, improved muscle recovery. Skin beginning to look more hydrated and elastic. Recovery from training noticeably faster. Sleep architecture optimized with more time in deep slow-wave sleep. IGF-1 levels elevated on bloodwork.
Weeks 6-16: Full body recomposition effects evident. Lean mass gains consolidated. Skin, hair, and nail quality improvements clearly visible. Joint and connective tissue health improved. Fat loss patterns established. Consider cycling off after 12-16 weeks with a 4-week break to maintain pituitary sensitivity.
Evidence
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Quick-start dose/route: 100 mcg CJC + 100 mcg Ipamorelin per injection, SubQ, 1-2x daily. GAP — UNSUPPORTED EXACT BLEND. Exact-blend searches found narrative reviews but no abstract administering this fixed formulation. Standalone Ipamorelin PMID 10496658 and swine PMID 9849822 do not verify the blend; PMID 16352683 is long-acting CJC-1295, not no-DAC Mod GRF(1-29).
Mechanism: simultaneous GHRH-receptor and GHS-R1a activation producing 3-5x synergistic GH pulses. GAP — UNSUPPORTED EXACT BLEND. No checked abstract measured this mechanism or the claimed amplification for the pre-mixed product.
Primary safety: favorable cortisol/prolactin profile and long-term blend tolerability. GAP — UNSUPPORTED EXACT BLEND. No abstract established human safety for this exact blend, route, dose, and repeated schedule.
The honest take
Ipamorelin is the cleanest GHRP with no cortisol or prolactin elevation
SupportedWell-supported by human PK/PD studies. At standard doses (100-300mcg), Ipamorelin produces minimal cortisol and prolactin elevation compared to GHRP-2 and GHRP-6. This selectivity is its primary clinical advantage.
Supported by human studies of GHRH + GHRP co-administration showing supra-additive GH release. The exact multiplier varies by individual and dose, but synergistic amplification is well-established in the literature.
Accurate. Unlike CJC-1295 with DAC (which creates sustained GH elevation), the no-DAC version produces discrete pulses that clear within 2-3 hours, maintaining the body's natural pulsatile rhythm.
Interactions & stacking
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Documented together
Keep separate
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
Side effects & safety
Commonly reported
- Transient flushing or warmth post-injection (resolves in minutes)
- Mild tingling or head rush immediately after injection
- Improved sleep quality and vivid dreams (desired effect)
- Mild water retention in first 1-2 weeks (subsides)
Less common & notes
- Rarely reported: headache, mild lethargy, temporary joint stiffness from water retention.
- Ipamorelin does NOT meaningfully elevate cortisol, prolactin, or aldosterone at standard doses - this is its key advantage over other GHRPs.
- Very high doses (above 300mcg Ipamorelin) provide no additional GH benefit and may increase side effects.
- Both components have favorable safety profiles in human studies, but long-term data for the combination beyond 6 months is limited.
Pharmacokinetics
CJC-1295 no DAC: ~30 min; Ipamorelin: ~2 hours. Combined GH pulse duration: 1.5-2 hours.
CJC: 15-30 min; Ipamorelin: 20-30 min. Peak synergistic GH release at ~25-35 min post-injection.
CJC cleared within 2-3 hours. Ipamorelin cleared within 6-8 hours. GH pulse elevation returns to baseline by 3-4 hours.
SubQ: ~95-100% for both components. Oral: not viable (peptide degradation in GI tract).
GH pulse lasts 1.5-2 hours. Downstream IGF-1 elevation persists 12-20 hours. No significant appetite, cortisol, or prolactin effects to track.
Enzymatic degradation by peptidases. CJC modifications provide DPP-IV resistance extending half-life 3-4x over native GHRH. Ipamorelin cleared by renal and hepatic peptidases.
Storage. Store lyophilized vial at room temperature or refrigerated. After reconstitution with bacteriostatic water, store refrigerated at 2-8 degrees C. Use within 28-30 days of reconstitution. Do not freeze after reconstitution. Protect from prolonged light exposure. Discard if solution becomes cloudy or contains particulate matter.
Regulatory status
Not FDA-approved as a combination product. Available through compounding pharmacies with prescription. CJC-1295 no DAC (Mod GRF 1-29) has published human pharmacokinetic data. Ipamorelin has Phase 2 clinical trial data for post-operative ileus. Pre-mixed blends are a compounding pharmacy product. Classified as research peptides in most jurisdictions. All use is experimental and off-label.
Put it to work
Calculate, log & track
Open CJC-1295 no DAC / Ipamorelin Blend straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open CJC-1295 no DAC / Ipamorelin Blend in the app →Go deeper
The guide & community
The complete CJC-1295 no DAC / Ipamorelin Blend walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗